Fangzheng Securities Research Report pointed out that Shierjia's medical and aesthetic pipeline breakthrough+ continuous iteration of new skincare products opens up room for growth. The company's first injectable Class III device “Shierjia Flower Season Kinetics” is expected to be launched in October. The company closed the “makeup - device - injection - repair” business and officially entered the aesthetic injection circuit. Other pipeline reserves: Recombinant type III humanized collagen freeze-dried fiber has been accepted by the National Drug Administration; various novel biomaterials such as collagen fillers, bacterial cellulose, and L-polylactic acid are also in the R&D testing phase. After the company completed the adjustment of the offline dealer system, the offline channel benefited from the increase brought about by the new distribution system, compounding the low base for the same period last year to achieve steady repair growth; new products from the online channel entered the matrix release stage, and the medical and aesthetic pipeline also entered the fulfillment period. The subsequent focus was on the continuous repair of offline channels, the release of new skincare products, and the pace of implementation of the medical and aesthetic pipeline matrix.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.